CARDIAC RSK3 INHIBITORS, LLC
Los Altos, CA · Biotech · Private
AAV9sc.RBD gene therapy vector that disrupts RSK3-mAKAPβ protein-protein interaction in cardiac myocytes to prevent pathological heart remodeling
- Grants
- $13M
- 8 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 2
- 0 granted · 2 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2019202020212022202320242025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · ShRNA-Based Targeting of mAKAPβ in Heart Failure | $332,445 | |
| Federal grant | Department of Health and Human Services · Phase II · ShRNA-Based Targeting of mAKAPβ in Heart Failure | $2,647,016 | |
| Federal grant | Department of Health and Human Services · Phase II · PP2A Anchoring Disruptor Therapy in Heart Failure | $436,929 | |
| Federal grant | Department of Health and Human Services · Phase II · ShRNA-Based Targeting of mAKAPβ in Heart Failure | $885,032 | |
| Federal grant | Department of Health and Human Services · Phase II · PP2A Anchoring Disruptor Therapy in Heart Failure | $3,108,018 | |
| Federal grant | Department of Health and Human Services · Phase II · PP2A Anchoring Disruptor Therapy in Heart Failure | $1,219,206 | |
| Federal grant | Department of Health and Human Services · Phase II · RSK3 Anchoring Disruptor Therapy for Heart Failure | $1,978,293 | |
| Federal grant | Department of Health and Human Services · Phase II · RSK3 Anchoring Disruptor Therapy for Heart Failure | $1,982,787 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3142 | MARWELL BIO INC. | — | — |
| 3143 | Iria Pharma, LLC | — | — |
| 3144 | DINYA DNA INC | — | $3.8M |
| 3145 | CARDIAC RSK3 INHIBITORS, LLC | — | — |
| 3146 | AJK BIOPHARMACEUTICAL LLC | — | — |
| 3147 | Kinetiq | — | — |
| 3148 | ExQor Technologies Inc | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Promoter-enhancer Sequences Of The Human Troponin T Gene For Selective Expression In Cardiac Myocytesapplication
- Promoter-enhancer Sequences Of The Human Troponin T Gene For Selective Expression In Cardiac Myocytesapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.